A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Condition:   Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment Intervention:   Drug: CAM-H2 Sponsor:   Camel-IDS NV Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients
Condition:   HER2 Positive Breast Cancer Intervention:   Drug: AIP-303 Sponsors:   Advanced Imaging Projects, LLC;   All India Institute of Medical Sciences, New Delhi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
Condition:   Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment Intervention:   Drug: CAM-H2 Sponsor:   Camel-IDS NV Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 13, 2020 Category: Research Source Type: clinical trials

A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
Condition:   HER2-amplified Biliary Tract Cancers Interventions:   Drug: ZW25 (Zanidatamab);   Diagnostic Test: In situ hybridization (ISH)-based companion diagnostic assay;   Diagnostic Test: Immunohistochemistry (IHC)-based companion diagnostic assay Sponsors:   Zymeworks Inc.;   BeiGene, Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 10, 2020 Category: Research Source Type: clinical trials

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Conditions:   Advanced Solid Tumor;   Metastatic Cancer;   HER2-positive Breast Cancer;   HER2-positive Gastric Cancer;   HER-2 Protein Overexpression;   Esophageal Cancer;   Ovarian Cancer;   Endometrium Cancer;   Bladder Cancer;   Pancreatic Cancer;   Colorectal Cancer;   Non Smal l Cell Lung Cancer;   EGF-R Positive Non-Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Triple Negati...
Source: ClinicalTrials.gov - July 9, 2020 Category: Research Source Type: clinical trials

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
Condition:   Breast Cancer Intervention:   Sponsor:   Pfizer Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 8, 2020 Category: Research Source Type: clinical trials

A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors
Condition:   HER2 Positive Solid Tumors Intervention:   Drug: SBT6050 Sponsor:   Silverback Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Conditions:   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC  v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer&nbs...
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
Conditions:   Triple-negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Sponsor:   Peking University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors
Condition:   HER2 Positive Solid Tumors Intervention:   Drug: SBT6050 Sponsor:   Silverback Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Conditions:   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC  v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer&nbs...
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
Conditions:   Triple-negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Sponsor:   Peking University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors
Condition:   HER2 Positive Solid Tumors Intervention:   Drug: SBT6050 Sponsor:   Silverback Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Conditions:   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC  v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer&nbs...
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
Conditions:   Triple-negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Sponsor:   Peking University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors
Condition:   HER2 Positive Solid Tumors Intervention:   Drug: SBT6050 Sponsor:   Silverback Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Conditions:   Anatomic Stage IA Breast Cancer AJCC v8;   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC  v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer&nbs...
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
Conditions:   Triple-negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Sponsor:   Peking University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors
Condition:   HER2 Positive Solid Tumors Intervention:   Drug: SBT6050 Sponsor:   Silverback Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer
Condition:   Breast Cancer Intervention:   Drug: Neratinib + endocrine therapy Sponsor:   SOLTI Breast Cancer Research Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
Conditions:   Triple-negative Breast Cancer;   HER2-positive Breast Cancer Intervention:   Sponsor:   Peking University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 7, 2020 Category: Research Source Type: clinical trials